Henlius falls short of IPO goal, but still rakes in $410M on HKEX

hong kong
The company earmarked 40% of the proceeds for the clinical development, regulatory filing and registration of its “Core Products,” which include biosimilars for the cancer drugs Herceptin and Avastin. (Pixabay)

Last week, Shanghai Henlius Biotech teed up for a $477 million IPO on the Hong Kong Stock Exchange. It fell a little short when it priced on Wednesday, ultimately bagging $410 million, but still made the top five biopharma IPOs so far this year. 

It is Hong Kong’s first major listing since that of Jinshang Bank in July, according to Bloomberg, and the first biopharma listing since Hansoh’s $1 billion debut in June. Henlius’ debut also comes amid antigovernment protests over an extradition bill that has since been withdrawn.

The company earmarked 40% of the proceeds for the clinical development, regulatory filing and registration of its “Core Products,” according to a filing with the HKEX. These include HLX02, a Herceptin biosimilar in phase 3 and HLX04, an Avastin biosimilar in phase 3 for metastatic colorectal cancer. Henlius is also testing HLX04 in combination with HLX10, an anti-PD-1 antibody, in non-small cell lung cancer and liver cancer. 

Virtual Roundtable

ASCO Explained: Expert predictions and takeaways from the world's biggest cancer meeting

Join FiercePharma for our ASCO pre- and post-show webinar series. We'll bring together a panel of experts to preview what to watch for at ASCO. Cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. Following the meeting, we’ll do a post-show wrap up to break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers.

RELATED: Atomwise takes on 2 more JVs, including a $1.5B project with China's Hansoh Pharma 

The rest of the proceeds will support the development of other biosimilars, as well as drug programs discovered at Henlius, including those targeting VEGF, EGFR and PD-L1. 

“We are currently conducting clinical trials of HLX06, HLX07, HLX10 and HLX20 and will further explore immuno-oncology combination therapies using immune checkpoint inhibitor such as PD-1/PD-L1 drugs,” Henlius said in the filing.

“We believe that the successful development and commercialisation of these products and therapies are key to our long-term sustainable development following the expected launch of our Core Products. As all of our CoreProducts have reached late-stage development in Phase 3 clinical trials or later, we believe that it is reasonable to allocate a significant portion of the expected net proceeds to the development of our other pipeline products and therapies,” the company said.

Suggested Articles

The FDA named more than two dozen coronavirus antibody tests that should be taken off the market weeks after the agency clamped down on tests.

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

The machine-learning programs scroll through data to detect hard-to-spot patterns. Yet few have been tested against standard procedures.